A post below raises the prospect that discussion of prescription drug counterfeiting might be “just another scare tactic of Big Pharma.”  That could be true, if such a discussion served mainly as a trojan horse argument against the reimportation of medicines from countries with highly developed health systems. Readers can make up their own minds whether that’s what is going on here.

But ask yourself this. If you were an uninsured patient unable to afford medication in the US, would you rather get your prescription filled in a Canadian pharmacy or go without? Me too.

And, as long as we are talking about scare tactics, I’m sure it won’t escape anyone’s notice that this blog is sponsored by a company that is in the business of supply chain management and product security.

That isn’t to say there aren’t real issues. Phony drugs in the developing world are a big problem. And as the US supply chain moves increasingly to some of these same countries, Americans, too, should be concerned. But they should also be wary of anyone who benefits from ginning up a drug scare.